The EGFR-Multiplex Set cfDNA in Plasma is a highly valuable reference material for research and diagnostics, particularly in the field of cancer detection. EGFR (Epidermal Growth Factor Receptor) mutations are well-known driver mutations, commonly found in cancers like lung and breast cancer. These mutations play a significant role in the development and progression of Non-Small Cell Lung Cancer (NSCLC), making the detection of EGFR mutations essential for effective therapeutic strategies.

The EGFR-Multiplex Set cfDNA in Plasma offers a selection of both TKI (tyrosine kinase inhibitor) sensitive and resistant mutations. This diverse range of mutations is crucial for understanding therapeutic responses and resistance mechanisms, ensuring more precise and personalized treatments for patients with NSCLC. By incorporating both TKI-sensitive and resistant mutations, the product enables comprehensive monitoring of EGFR-related therapy responses, contributing to better clinical outcomes.

This product is designed for use in diagnostic laboratories and research settings, where it can serve as a positive control in liquid biopsy assays. The EGFR-Multiplex Set cfDNA in Plasma is also ideal for the validation and development of EGFR diagnostic kits, supporting the ongoing evolution of more effective cancer diagnostic tools. The cfDNA used in this product is sourced from the Ashkenazim Son cell line and combined with human-tech plasma, ensuring high-quality, clinically relevant material for accurate testing and assay development.

Whether you are working in a laboratory setting or conducting cutting-edge research in the development of EGFR diagnostics, the EGFR-Multiplex Set cfDNA in Plasma provides the reliable and relevant material needed to drive accurate and effective results. With its use, researchers can advance the understanding of EGFR mutations, improve liquid biopsy assays, and enhance the diagnosis and treatment of NSCLC and other cancers driven by EGFR mutations.